IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis

Abstract

Background: Denosumab is a human monoclonal antibody that binds to receptor activator of nuclear factor kappa-B ligand (RANKL). This inhibits the binding of RANKL to RANK on osteoclasts which reduces the activity of osteoclasts and avoids bone loss, and thus increases bone density. In addition, recent studies also showed that Denosumab seems to suppress blood sugar, but the underline mechanism is still unknown. Interestingly, some studies revealed the glucose-lowering effects by Denosumab may be related to the protection of β cells.